Full Doc
 | 2002 |
Visteon Appoints Thomas T. Stallkamp and Michael F. Johnston to Board of Directors
Visteon Appoints Thomas T. Stallkamp and Michael F. Johnston to Board of Directors (4K)
Doc #271617: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}EX-99.1
{SEQUENCE}3
{FILENAME}k68829ex99-1.txt
{DESCRIPTION}NEWS RELEASE DATED APRIL 10, 2002
{TEXT}
{PAGE}
EXHIBIT 99.1
Contact(s): Media Inquiries: Visteon Corporation
Greg Gardner Public Affairs
313-755-0927 5500 Auto Club Drive
ggardne9@visteon.com Dearborn, MI 48126
Facsimile: 313-755-7983
Investor inquiries:
Derek Fiebig
313-755-3699
dfiebig@visteon.com
[VISTEON LOGO]
VISTEON APPOINTS THOMAS T. STALLKAMP AND
MICHAEL F. JOHNSTON TO BOARD OF DIRECTORS
DEARBORN, Mich., April 10, 2001 - Visteon Corporation (NYSE: VC) today announced
that its Board of Directors has appointed Thomas T. Stallkamp and Michael F.
Johnston as members of the Board.
Thomas T. Stallkamp has served as Vice Chairman and Chief Executive Officer of
MSX International Inc. since January 2000. MSX provides contract staffing and
project engineering services to the automotive and telecommunications
industries.
Prior to his position at MSX, Stallkamp was Vice Chairman of DaimlerChrysler
Corporation where he also served as its President and a member of its board of
management. During his nearly 20 years at DaimlerChrysler, Stallkamp became
known for developing new business processes and enhanced partnerships with the
automotive supply community. He pioneered the development of a unique
partnership approach to corporate supplier relations under Chrysler's Extended
Enterprise concept.
Michael F. Johnston is Visteon's President and Chief Operation Officer, leading
the company's global operations, sales, manufacturing, product development,
1.
{PAGE}
research and development and customer relations. Johnston came to Visteon in
September 2000 from Johnson Controls Inc., where he was President of E-Business.
In that position he was responsible for launching and growing new businesses,
including non-automotive ventures that used the Internet to streamline supply
chain management and to serve customers more effectively.
"We're delighted to have Tom and Mike join the Board," Peter J. Pestillo,
Visteon's Chairman and Chief Executive Officer said. "Tom is widely regarded as
a leader and innovator in the supplier community. In electing Mike, the Visteon
Board has recognized Mike's substantial contributions and his leadership in
improving Visteon's performance and customer orientation."
Stallkamp serves on the boards of Kmart Corporation and Baxter International
Inc. He is on the board of advisors of Georgetown University's McDonough School
of Business and teaches at Babson College's Graduate Entrepreneurship Center. He
holds a bachelor's degree in industrial management and economics and a master's
degree in business administration from Miami University in Oxford, Ohio.
Johnston serves on the boards of directors of Flowserve Corporation in Irving,
Texas, and the Original Equipment Suppliers Association. He holds a bachelor's
degree in industrial management from the University of Massachusetts at Lowell
and a master's degree in business administration from Michigan State
University's Executive Program.
Stallkamp and Johnston join Pestillo, William Gray, Steven Hamp, Kathleen
Hempel, Robert Jenkins, Charles Schaffer and Robert Teeter on the Board.
Visteon Corporation is a leading full-service supplier that delivers
consumer-driven technology solutions to automotive manufacturers worldwide and
through multiple channels within the global automotive aftermarket. Visteon has
about 79,000 employees and a global delivery system of more than 180 technical,
manufacturing, sales and service facilities located in 25 countries.
###
Visteon news releases, photographs and product specification details
are available at www.visteon.com
2.
{/TEXT}
{/DOCUMENT}
271617
|
Visteon
As referenced in this Visteon Appoints Thomas T. Stallkamp and Michael F. Johnston to Board of Directors:
Visteon Corp – 1
{SEQUENCE}3
{FILENAME}k68829ex99-1.txt
{DESCRIPTION}NEWS RELEASE DATED APRIL 10, 2002
{TEXT}
{PAGE}
EXHIBIT 99.1
Contact(s): Media Inquiries: Visteon Corp oration
Greg Gardner Public Affairs
313-755-0927 5500 Auto Club Drive
ggardne9@visteon.com Dearborn, MI 48126
Facsimile: 313-755-7983
Investor
_____________
Visteon Corp – dfiebig@visteon.com
[VISTEON LOGO]
VISTEON APPOINTS THOMAS T. STALLKAMP AND
MICHAEL F. JOHNSTON TO BOARD OF DIRECTORS
DEARBORN, Mich., April 10, 2001 - Visteon Corp oration (NYSE: VC) today announced
that its Board of Directors has appointed Thomas T. Stallkamp and Michael F.
Johnston as members of the
_____________
Visteon Corp – Executive Program.
Stallkamp and Johnston join Pestillo, William Gray, Steven Hamp, Kathleen
Hempel, Robert Jenkins, Charles Schaffer and Robert Teeter on the Board.
Visteon Corp oration is a leading full-service supplier that delivers
consumer-driven technology solutions to automotive manufacturers worldwide and
through multiple channels within the
_____________
dt 178571
| |
Preview
Full Doc
| 2002 |
Interneuron Pharmaceuticals Announces Private Placement
Interneuron Pharmaceuticals Announces Private Placement (2K)
Doc #274159: Click preview link for longer preview.
{DOCUMENT}
{TYPE}EX-99.1
{SEQUENCE}4
{FILENAME}dex991.txt
{DESCRIPTION}PRESS RELEASE DATED 12/20/2001
{TEXT}
{PAGE}
EXHIBIT 99.1
FOR IMMEDIATE RELEASE
---------------------
CONTACT, AT (781) 861-8444:
MICHAEL W. ROGERS WILLIAM B. BONI
EXEC. VP AND CHIEF FINANCIAL OFFICER VP, CORP. COMMUNICATIONS
INTERNEURON PHARMACEUTICALS ANNOUNCES PRIVATE PLACEMENT
LEXINGTON, MA, December 20, 2001 -- Interneuron Pharmaceuticals, Inc. (NASDAQ:
IPIC) today announced that it had entered into agreements with a group of
institutional investors and one of their affiliates to sell approximately 2.5
million shares of newly issued Interneuron common stock in a private placement,
resulting in $20 million in gross proceeds to Interneuron. Legg Mason Wood
Walker, Inc. acted as the placement agent for this transaction.
The Company plans to use the proceeds of the private placement to support
product development and business development activities. In addition, the
Company may use a portion of the net proceeds for working capital and general
corporate purposes.
These securities have not been registered under the Securities Act of 1933, as
amended, or state securities laws and may not be offered or sold in the United
States absent registration or an applicable exemption from the registration
requirements.
Interneuron Pharmaceuticals is engaged in the development and commercialization
of a portfolio of products and product candidates for panic/anxiety disorders,
overactive bladder, inflammatory bowel disease, prevention of HIV infection,
stroke and other disorders.
Except for the descriptions of historical facts contained herein, this press
release contains forward-looking statements that involve risks and uncertainties
that could cause the Company's actual results and financial condition to differ
materially from those anticipated by the forward looking statements. These
risks and uncertainties are set forth in the Company's filings under the
Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk
Factors" and elsewhere, and include, but are not limited to: the early stage of
products under development; uncertainties relating to clinical trials and
regulatory approvals; dependence on third parties for manufacturing and
marketing; need for additional funds and corporate partners; history of
operating losses and expectation of future losses; product liability; risks
relating to the Redux-related litigation; government regulation, patent risks
and competition.
###
{/TEXT}
{/DOCUMENT}
274159
| |
 Legg Mason
As referenced in this Interneuron Pharmaceuticals Announces Private Placement:
Legg Mason Wood
Walker, – 2.5
million shares of newly issued Interneuron common stock in a private placement,
resulting in $20 million in gross proceeds to Interneuron. Legg Mason Wood
Walker, Inc. acted as the placement agent for this transaction.
The Company plans to use the proceeds of the private placement to support
_____________
dt 186539
|
Preview
Full Doc
| 2002 |
Interneuron Pharmaceuticals Closes Previously Announced Private Financing, Raises $25 Million
Interneuron Pharmaceuticals Closes Previously Announced Private Financing, Raises $25 Million (2K)
Doc #274160: Click preview link for longer preview.
{DOCUMENT}
{TYPE}EX-99.2
{SEQUENCE}5
{FILENAME}dex992.txt
{DESCRIPTION}PRESS RELEASE DATED 12/21/2001
{TEXT}
{PAGE}
EXHIBIT 99.2
------------
FOR IMMEDIATE RELEASE
---------------------
Contact, at (781) 861-8444:
Michael W. Rogers William B. Boni
Exec. VP and Chief Financial Officer VP, Corp. Communications
INTERNEURON PHARMACEUTICALS CLOSES
PREVIOUSLY ANNOUNCED PRIVATE FINANCING, RAISES $25 MILLION
LEXINGTON, MA, December 21, 2001 -- Interneuron Pharmaceuticals, Inc. (NASDAQ:
IPIC) today announced the completion of a previously announced private placement
of shares of newly issued Interneuron common stock to a group of institutional
investors and their affiliates. This placement raised $25 million in gross
proceeds from the sale of 3.125 million shares. Legg Mason Wood Walker, Inc.
acted as the placement agent for this transaction.
The Company plans to use the proceeds of the private placement to support
product development and business development activities. In addition, the
Company may use a portion of the net proceeds for working capital and general
corporate purposes.
These securities have not been registered under the Securities Act of 1933, as
amended, or state securities laws and may not be offered or sold in the United
States absent registration or an applicable exemption from the registration
requirements.
Interneuron Pharmaceuticals is engaged in the development and commercialization
of a portfolio of products and product candidates for panic/anxiety disorders,
overactive bladder, inflammatory bowel disease, prevention of HIV infection,
stroke and other disorders.
Except for the descriptions of historical facts contained herein, this press
release contains forward-looking statements that involve risks and uncertainties
that could cause the Company's actual results and financial condition to differ
materially from those anticipated by the forward looking statements. These
risks and uncertainties are set forth in the Company's filings under the
Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk
Factors" and elsewhere, and include, but are not limited to: the early stage of
products under development; uncertainties relating to clinical trials and
regulatory approvals; dependence on third parties for manufacturing and
marketing; need for additional funds and corporate partners; history of
operating losses and expectation of future losses; product liability; risks
relating to the Redux-related litigation; government regulation, patent risks
and competition.
###
{/TEXT}
{/DOCUMENT}
274160
| |
Legg Mason
As referenced in this Interneuron Pharmaceuticals Closes Previously Announced Private Financing, Raises $25 Million:
Legg Mason Wood Walker, – group of institutional
investors and their affiliates. This placement raised $25 million in gross
proceeds from the sale of 3.125 million shares. Legg Mason Wood Walker, Inc.
acted as the placement agent for this transaction.
The Company plans to use the proceeds of the private placement to support
_____________
dt 186540
|
| Full Doc
| 2002 |
Isis Pharmaceuticals and Circadian Technologies Form Antisense Therapeutics Limited
Isis Pharmaceuticals and Circadian Technologies Form Antisense Therapeutics Limited (7K)
Doc #282228: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}EX-99.2
{SEQUENCE}11
{FILENAME}a2067158zex-99_2.txt
{DESCRIPTION}EXHIBIT 99.2
{TEXT}
{Page}
ISIS PHARMACEUTICALS AND CIRCADIAN TECHNOLOGIES FORM ANTISENSE THERAPEUTICS
LIMITED
NEW AUSTRALIAN COMPANY FURTHERS ISIS' STRATEGY TO BROADEN APPLICATION OF
ANTISENSE TECHNOLOGY
Carlsbad, CA, USA and Melbourne, Australia, December 19, 2001 - Isis
Pharmaceuticals, Inc. (NASDAQ: ISIP) and Circadian Technologies Limited (ASX:
CIR), a leading Australian biotechnology commercialization firm, announced today
the companies have collaborated to create Antisense Therapeutics Limited (ATL).
Isis and Circadian have established this new Australian-based biotechnology
company to focus on the discovery and development of antisense drugs. ATL will
further the application of Isis' antisense technology platform in new markets.
ATL was listed on the Australian Stock Exchange (ASX) today under the symbol
ANP, successfully completing its initial public offering.
As part of establishing ATL in the antisense field, Isis has licensed to ATL
ISIS 107248, an antisense inhibitor to CD 49d, a sub-unit of VLA-4 (Very Late
Antigen-4). Treatment by inhibition of VLA-4 has been demonstrated to have
positive effects in animal models of a number of inflammatory diseases such as
multiple sclerosis. Isis will complete the required preclinical studies for ISIS
107248 and will manufacture drug for human clinical trials at ATL's expense. ATL
will undertake future clinical development and commercialization of the
compound.
Isis and ATL will also participate in a five-year antisense drug discovery and
development collaboration, which includes ATL's use of GeneTrove's-TM- gene
functionalization services for a limited number of targets. ATL will pay Isis
for access to the company's antisense expertise and for research and
manufacturing services conducted during the collaboration. In addition, ATL will
pay to Isis royalties on antisense drugs discovered and developed within the
partnership. Isis owns approximately 14 percent of ATL equity and holds options
for additional shares. Isis' Chairman and CEO Stanley T. Crooke, M.D., Ph.D., is
a member of ATL's Board of Directors.
"In partnership with Circadian, we are very pleased to have formed a new company
focused solely on exploiting antisense technology as a drug discovery and
development platform. Our goals from the outset have been to lead the industry
into antisense technology and encourage its use broadly. ATL is another example
of our execution of these goals, on a global level," said Stanley T. Crooke,
M.D., Ph.D., Isis' Chairman and Chief Executive Officer. "At Isis, we currently
discover more potential drug candidates than we can afford to develop. ATL
represents a strategic move to broaden the reach of antisense drugs, while
minimizing financial obligations for us and our shareholders."
To build its business, ATL will engage in antisense drug discovery and
development collaborations with academic research institutions throughout
Australia, including the prestigious Murdoch Childrens Research Institute based
in Melbourne. Murdoch Childrens Research Institute will contribute key specific
intellectual property and expertise to ATL's antisense research efforts. In the
future, ATL plans to work with additional corporate partners.
"Antisense is a revolutionary drug discovery platform that has progressed
significantly over the last decade and is now prime for broad application. We
look forward to working with Isis, the undisputed leader in antisense, as our
key technology partner. We have created a powerful team and business plan to
expand the investigation and development of this important platform technology
into new therapeutics for patients in need," said Chris Belyea, ATL's founding
Chief Executive Officer.
ATL's IPO raised A$13 million (Australian dollars), or US$6.5 million. Circadian
directly and indirectly holds 36 percent of ATL issued capital.
"In recent years we have worked successfully to establish several listed
Australian biotechnology companies and we are delighted to be involved in this
collaboration with Isis who we regard as the pioneer of antisense technology,"
said Leon Serry, Circadian's Chief Executive Officer.
Circadian Technologies Limited was listed on the ASX in 1985. Circadian provides
management and funding for the development and commercialization of Australian
pharmaceutical research to the stage of either licensing or listing on the ASX.
The company holds equity positions in Metabolic Pharmaceuticals Limited
(developing a new obesity drug - ASX: MBP), Optiscan Imaging Limited (developing
new diagnostic imaging equipment -ASX: OIL), and U.S.-based Axon Instruments,
Inc. (genomics and high throughput screening equipment - ASX: AXN). For these
{Page}
companies, Circadian provided funding and assistance in their listings on the
ASX. Circadian is also now the largest shareholder in AMRAD Corporation Limited
(with three drugs in Phase II trials - ASX: AML). Circadian's current unlisted
R&D portfolio includes a novel platform technology for identification of
potential cancer markers and an extensive patent portfolio in in situ
hybridization techniques.
Isis Pharmaceuticals, Inc. is exploiting its expertise in RNA to discover and
develop novel human therapeutic drugs. The company has commercialized its first
product, Vitravene-Registered Trademark- (fomivirsen), to treat CMV-induced
retinitis in AIDS patients. In addition, Isis has 13 products in its development
pipeline with two in Phase III and seven in Phase II human clinical trials. ISIS
3521, an inhibitor of PKC-alpha, is in Phase III trials for non-small cell lung
cancer and alicaforsen (ISIS 2302), an ICAM-1 inhibitor, is also in Phase III
trials for Crohn's disease. Isis has a broad patent estate as the owner or
exclusive licensee of nearly 900 issued patents worldwide. Isis' GeneTrove
division uses antisense to assist pharmaceutical industry partners in validating
and prioritizing potential gene targets through customized services and access
to an extensive gene function database. Ibis Therapeutics-TM- is a division
focused on the discovery of small molecule drugs that bind to RNA. Additional
information about Isis is available at www.isip.com.
This press release contains forward-looking statements concerning the potential
of Isis Pharmaceuticals, antisense technology as a drug discovery and
development platform and a tool for functional genomics, the prospects of ISIS
107248 as a treatment for multiple sclerosis and Isis' relationship with ATL and
Circadian Technologies. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of discovering,
developing and commercializing drugs that are safe and effective for use as
human therapeutics and financing such activities. Actual results could differ
materially from those projected in this release. As a result, you are cautioned
not to rely on these forward-looking statements. These and other risks
concerning Isis' research and development programs are described in additional
detail in the Company's Quarterly Report on Form 10Q, for the period ended
September 30, 2001, which is on file with the U.S. Securities and Exchange
Commission, copies of which are available from the company.
Vitravene-Registered Trademark- is a trademark of Novartis AG.
GeneTrove-TM- and Ibis Therapeutics-TM- are trademarks of Isis Pharmaceuticals,
Inc.
{/TEXT}
{/DOCUMENT}
282228
|
ISIS Pharma
As referenced in this Isis Pharmaceuticals and Circadian Technologies Form Antisense Therapeutics Limited:
ISIS PHARMACEUTICALS – {DOCUMENT}
{TYPE}EX-99.2
{SEQUENCE}11
{FILENAME}a2067158zex-99_2.txt
{DESCRIPTION}EXHIBIT 99.2
{TEXT}
{Page}
ISIS PHARMACEUTICALS AND CIRCADIAN TECHNOLOGIES FORM ANTISENSE THERAPEUTICS
LIMITED
NEW AUSTRALIAN COMPANY FURTHERS ISIS' STRATEGY TO BROADEN APPLICATION OF
ANTISENSE TECHNOLOGY
Carlsbad, CA, USA and
_____________
Isis
Pharmaceuticals, – THERAPEUTICS
LIMITED
NEW AUSTRALIAN COMPANY FURTHERS ISIS' STRATEGY TO BROADEN APPLICATION OF
ANTISENSE TECHNOLOGY
Carlsbad, CA, USA and Melbourne, Australia, December 19, 2001 - Isis
Pharmaceuticals, Inc. (NASDAQ: ISIP) and Circadian Technologies Limited (ASX:
CIR), a leading Australian biotechnology commercialization firm, announced today
the companies have collaborated to
_____________
Isis Pharmaceuticals, – D portfolio includes a novel platform technology for identification of
potential cancer markers and an extensive patent portfolio in in situ
hybridization techniques.
Isis Pharmaceuticals, Inc. is exploiting its expertise in RNA to discover and
develop novel human therapeutic drugs. The company has commercialized its first
product,
_____________
Isis Pharmaceuticals, – to RNA. Additional
information about Isis is available at www.isip.com.
This press release contains forward-looking statements concerning the potential
of Isis Pharmaceuticals, antisense technology as a drug discovery and
development platform and a tool for functional genomics, the prospects of ISIS
107248 as a
_____________
Isis Pharmaceuticals, – are available from the company.
Vitravene-Registered Trademark- is a trademark of Novartis AG.
GeneTrove-TM- and Ibis Therapeutics-TM- are trademarks of Isis Pharmaceuticals,
Inc.
{/TEXT}
{/DOCUMENT}
_____________
dt 219667
| |
| Full Doc
| 2002 |
Isis Pharmaceuticals Establishes New Supply Agreement and Broadens License To Key Antisense Intellectual Property
Isis Pharmaceuticals Establishes New Supply Agreement and Broadens License To Key Antisense Intellectual Property (7K)
Doc #282229: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}EX-99.3
{SEQUENCE}12
{FILENAME}a2067158zex-99_3.txt
{DESCRIPTION}EXHIBIT 99.3
{TEXT}
{Page}
ISIS PHARMACEUTICALS ESTABLISHES NEW SUPPLY AGREEMENT AND BROADENS LICENSE
TO KEY ANTISENSE INTELLECTUAL PROPERTY
Carlsbad, CA and Coraville, IA December 27, 2001 -- Isis Pharmaceuticals, Inc.
(NASDAQ: ISIP) announced today it has established a long-term research-scale
antisense inhibitor supply agreement with Integrated DNA Technologies, Inc.
(IDT). IDT is a leading supplier of antisense inhibitors used in research.
Additionally, Isis has further solidified its intellectual property leadership
position in antisense technology by broadening its license to certain antisense
patents.
In the long-term supply agreement Isis has initiated with IDT, IDT will
manufacture research-scale antisense inhibitors and research reagents to Isis
specifications. The agreement enables Isis to meet increasing demand for
functional genomics services that its GeneTrove division provides to a growing
number of major pharmaceutical and biotechnology customers. Isis will pay IDT $5
million toward Isis' future purchase of antisense inhibitors from IDT. The
transaction provides IDT with financing for the company's operations expansion.
Consistent with Isis' goal of broad control of intellectual property associated
with antisense technology, Isis has expanded its existing licensing agreement
with IDT on certain patents, which are useful in functional genomics and in
making certain antisense drugs. The expanded license allows Isis to exclusively
sublicense this intellectual property for functional genomics purposes. The
agreement also eliminates milestone payments and significantly reduces royalty
rates associated with commercialized second-generation antisense drugs. Isis
will pay IDT $4.9 million for the broadened intellectual property license.
Isis' intellectual property estate is comprised of nearly 900 issued patents
that Isis owns or exclusively licenses, covering RNA-based drug discovery and
development. The company's functional genomics suite of patents is made up of
approximately 50 patents and applications. This functional genomics suite of
patents broadly covers the use of RNA/DNA oligonucleotides, or antisense
inhibitors, in gene functionalization and target validation, including:
chemistries; antisense inhibitor designs called "motifs;" methods of use of
antisense inhibitors; and mechanisms of action by which antisense inhibitors
inactivate an RNA target.
"Our GeneTrove division has enjoyed tremendous success this year, adding Celera,
Lilly and Chiron to its roster of collaborators. The supply agreement we've
initiated augments our capacity to support these programs and continue to build
our GeneTrove business," said B. Lynne Parshall, Isis Executive Vice President
and Chief Financial Officer. "Importantly, this transaction enhances Isis'
intellectual property licensing program and supports our control over
second-generation antisense drugs, which we believe offer broad potential to
treat a wide range of diseases. It also improves the economics of the
second-generation drugs we develop."
"IDT is pleased to enter into this licensing agreement with an established
partner like Isis, and to continue to be a principle supplier of antisense
inhibitors and research reagents for Isis' research and development programs,
and to Isis' growing list of licensees and collaborators," said Joseph A.
Walder, M.D., Ph.D., President and CEO of IDT. "Importantly for IDT, this
transaction fortifies our financial position and facilitates our growth to meet
market demand in the ever-expanding global life sciences market."
Isis Pharmaceuticals, Inc. is exploiting its expertise in RNA to discover and
develop novel human therapeutic drugs. The company has commercialized its first
product, Vitravene-Registered Trademark- (fomivirsen), to treat CMV-induced
retinitis in AIDS patients. In addition, Isis has 13 products in its development
pipeline with two in Phase III and seven in Phase II human clinical trials. ISIS
3521, an inhibitor of PKC-alpha, is in Phase III trials for non-small cell lung
cancer, and alicaforsen (ISIS 2302), an ICAM-1 inhibitor, is also in Phase III
trials for Crohn's disease. Isis has a broad patent estate as the owner or
exclusive licensee of nearly 900 issued patents worldwide. Isis' GeneTrove-TM-
division uses antisense to assist pharmaceutical industry partners in validating
and prioritizing potential gene targets through customized services and access
to an extensive gene function database. Ibis Therapeutics-TM- is a division
focused on the discovery of small molecule drugs that bind to RNA. Additional
information about Isis is available at www.isip.com.
Integrated DNA Technologies, Inc., an Iowa-based biotechnology company, was
founded in 1987 by Dr. Joseph A. Walder. Dr. Walder has continued with the
company and is presently Corporate President and CEO. The company initially
worked as a research facility in the antisense area, and continues research
programs in nucleic acids and
{Page}
related chemistries. The company has patented technology, which it has
licensed to other companies as well as patents pending. Since 1992 the
company has produced chemical/biological items used by researchers in the
biotechnology industry focusing on short segment DNA. With over 300
employees, including a national and international sales force, IDT services
over 16,000 customers in fifty countries around the globe. IDT is a
recognized world leader in advancing biotechnology research as both a
supplier of oligonucleotides and an innovator of new technology.
Integrated DNA Technologies' production facility is located in Coralville,
Iowa near the University of Iowa, which has one of the largest medical
complexes and medical teaching facilities in the country. The region is one
of the fastest growing high tech corridors in the United States. The company
also has a corporate office in the Chicago area. Integrated DNA Technologies,
Inc. is dedicated to being the world's leader in innovation and precision in
nucleic acid synthesis. Additional information about IDT may be found on its
web site at www.idtdna.com.
This press release contains forward-looking statements concerning Isis
Pharmaceuticals and the potential of the company's intellectual property
position and Isis' current and future relationship with IDT. Such statements
are subject to certain risks and uncertainties, particularly those inherent
in the process of discovering, developing and commercializing drugs that are
safe and effective for use as human therapeutics and financing such
activities. Actual results could differ materially from those projected in
this release. As a result, you are cautioned not to rely on these
forward-looking statements. These and other risks concerning Isis' research
and development programs are described in additional detail on Quarterly
Report on Form 10-Q for the period ended September 30, 2001 which is on file
with the U.S. Securities and Exchange Commission, copies of which are
available from the company.
Vitravene-Registered Trademark- is a trademark of Novartis AG.
GeneTrove-TM- and Ibis Therapeutics-TM- are trademarks of Isis Pharmaceuticals,
Inc.
{/TEXT}
{/DOCUMENT}
282229
|
ISIS Pharma
As referenced in this Isis Pharmaceuticals Establishes New Supply Agreement and Broadens License To Key Antisense Intellectual Property:
ISIS PHARMACEUTICALS – {DOCUMENT}
{TYPE}EX-99.3
{SEQUENCE}12
{FILENAME}a2067158zex-99_3.txt
{DESCRIPTION}EXHIBIT 99.3
{TEXT}
{Page}
ISIS PHARMACEUTICALS ESTABLISHES NEW SUPPLY AGREEMENT AND BROADENS LICENSE
TO KEY ANTISENSE INTELLECTUAL PROPERTY
Carlsbad, CA and Coraville, IA December 27, 2001 -- Isis Pharmaceuticals, Inc.
(
_____________
Isis Pharmaceuticals, – Page}
ISIS PHARMACEUTICALS ESTABLISHES NEW SUPPLY AGREEMENT AND BROADENS LICENSE
TO KEY ANTISENSE INTELLECTUAL PROPERTY
Carlsbad, CA and Coraville, IA December 27, 2001 -- Isis Pharmaceuticals, Inc.
(NASDAQ: ISIP) announced today it has established a long-term research-scale
antisense inhibitor supply agreement with Integrated DNA Technologies, Inc.
(
_____________
Isis Pharmaceuticals, – IDT, this
transaction fortifies our financial position and facilitates our growth to meet
market demand in the ever-expanding global life sciences market."
Isis Pharmaceuticals, Inc. is exploiting its expertise in RNA to discover and
develop novel human therapeutic drugs. The company has commercialized its first
product,
_____________
Isis
Pharmaceuticals – Additional information about IDT may be found on its
web site at www.idtdna.com.
This press release contains forward-looking statements concerning Isis
Pharmaceuticals and the potential of the company's intellectual property
position and Isis' current and future relationship with IDT. Such statements
are subject to
_____________
Isis Pharmaceuticals, – are
available from the company.
Vitravene-Registered Trademark- is a trademark of Novartis AG.
GeneTrove-TM- and Ibis Therapeutics-TM- are trademarks of Isis Pharmaceuticals,
Inc.
{/TEXT}
{/DOCUMENT}
_____________
dt 219668
| |
Preview
Full Doc
| 2002 |
Cephalon, Inc. Completes Acquisition of France's Group Lafon
Cephalon, Inc. Completes Acquisition of France's Group Lafon (4K)
Doc #297312: Click preview link for longer preview.
{DOCUMENT}
{TYPE}EX-99.1
{SEQUENCE}7
{FILENAME}a2067212zex-99_1.txt
{DESCRIPTION}EXHIBIT 99.1
{TEXT}
{PAGE}
EXHIBIT 99.1
[CEPHALON LOGO] News
CEPHALON CONTACT:
Robert W. Grupp
1-610-738-6402
rgrupp@cephalon.com
FOR IMMEDIATE RELEASE
CEPHALON, INC. COMPLETES ACQUISITION OF FRANCE'S GROUP LAFON
WEST CHESTER, PA, December 28, 2001 - Cephalon, Inc. (Nasdaq: CEPH)
announced today that it has completed its previously announced acquisition of
the French pharmaceutical company Group Lafon.
With this acquisition, Cephalon now controls worldwide rights to its
flagship product PROVIGIL(R) (modafinil) Tablets [C-IV] and has acquired Lafon's
manufacturing facilities in Mitry-Mory where the active drug substance found in
PROVIGIL is produced. Cephalon also has acquired the entire portfolio of Lafon
products sold in France and the commercial operations of Laboratoire L. Lafon.
The French company will operate as a wholly owned subsidiary of Cephalon.
"This acquisition is important both strategically and financially, and we
are pleased with the rapid closure of the transaction," said Frank Baldino, Jr.,
Ph.D., Chairman and Chief Executive Officer of Cephalon. "The process of
integrating our two organizations - which began soon after the acquisition was
announced in early December - is going extremely well. We believe this
acquisition will enable us to quickly and significantly strengthen our position
in Europe."
Cephalon, Inc., headquartered in West Chester, Pennsylvania, is an
international biopharmaceutical company that discovers, develops and markets
products to treat neurological and sleep disorders, cancer and pain.
In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking statements
provide Cephalon's current expectations or forecasts of future events. These may
include statements regarding the timing of the integration of Lafon into
Cephalon's business, the impact of the acquisition on Cephalon's position in
Europe, anticipated scientific progress on its research programs,
{PAGE}
development of potential pharmaceutical products, interpretation of clinical
results, prospects for regulatory approval, manufacturing development and
capabilities, market prospects for its products, sales and earnings projections,
and other statements regarding matters that are not historical facts. You may
identify some of these forward-looking statements by the use of words in the
statements such as "anticipate," "estimate," "expect," "project," "intend,"
"plan," "believe" or other words and terms of similar meaning. Cephalon's
performance and financial results could differ materially from those reflected
in these forward-looking statements due to general financial, economic,
regulatory and political conditions affecting the biotechnology and
pharmaceutical industries as well as more specific risks and uncertainties such
as those set forth below and in its reports on Form 8-K, 10-Q and 10-K filed
with the U.S. Securities and Exchange Commission. Given these risks and
uncertainties, any or all of these forward-looking statements may prove to be
incorrect. Therefore, you should not rely on any such factors or forward-looking
statements. Furthermore, Cephalon does not intend to update publicly any
forward-looking statements, except as required by law. The Private Securities
Litigation Reform Act of 1995 permits this discussion.
# # #
{/TEXT}
{/DOCUMENT}
297312
|
Cephalon
As referenced in this Cephalon, Inc. Completes Acquisition of France's Group Lafon:
CEPHALON, INC – TEXT}
{PAGE}
EXHIBIT 99.1
[CEPHALON LOGO] News
CEPHALON CONTACT:
Robert W. Grupp
1-610-738-6402
rgrupp@cephalon.com
FOR IMMEDIATE RELEASE
CEPHALON, INC . COMPLETES ACQUISITION OF FRANCE'S GROUP LAFON
WEST CHESTER, PA, December 28, 2001 - Cephalon, Inc. (Nasdaq: CEPH)
announced today that it has
_____________
Cephalon, Inc – 738-6402
rgrupp@cephalon.com
FOR IMMEDIATE RELEASE
CEPHALON, INC. COMPLETES ACQUISITION OF FRANCE'S GROUP LAFON
WEST CHESTER, PA, December 28, 2001 - Cephalon, Inc . (Nasdaq: CEPH)
announced today that it has completed its previously announced acquisition of
the French pharmaceutical company Group Lafon.
With this acquisition,
_____________
Cephalon, Inc – in early December - is going extremely well. We believe this
acquisition will enable us to quickly and significantly strengthen our position
in Europe."
Cephalon, Inc ., headquartered in West Chester, Pennsylvania, is an
international biopharmaceutical company that discovers, develops and markets
products to treat neurological and sleep disorders,
_____________
dt 256099
;
| Group Lafon
|
| Full Doc
| 2002 |
Anthem, Inc. Reports Record Results for Fourth Quarter and Full Year 2001
Anthem, Inc. Reports Record Results for Fourth Quarter and Full Year 2001 (42K)
Doc #301236: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}EX-99
{SEQUENCE}3
{FILENAME}dex99.txt
{DESCRIPTION}PRESS RELEASE DATED FEBRUARY 6, 2002
{TEXT}
{PAGE}
EXHIBIT 99
news release Anthem, Inc.
120 Monument Circle
Indianapolis, IN 46204
Tel 317 488-6390
Fax 317 488-6460
[Anthem(R) LOGO APPEARS HERE]
Contacts: Investor Relations
Tami Durle, 317-488-6390
Media
Lauren Green-Caldwell, 317-488-6321
Anthem, Inc. Reports Record Results for Fourth Quarter and Full Year 2001
. Earnings per share increased 56% in the fourth quarter and 51% for the
full year before net realized gains and non-recurring items
. Operating gain increased 67% in the fourth quarter and 74% for the
full year
. Same store membership increased 10% to 7.9 million in 2001
. Operating cash flow exceeded $650 million in 2001
. Board approves $400 million stock repurchase program
. EPS guidance for 2002 increased by $0.10, to $3.65 - $3.75 per share
Indianapolis, IN - February 6, 2002 - Anthem, Inc. (NYSE: ATH) today reported
that net income for the fourth quarter of 2001 increased 21% to $87.7 million,
or $0.85 per share, compared with net income of $72.2 million, or $0.70 per
share, for the fourth quarter of 2000. Net income, excluding net realized gains
and other non-recurring items, for the fourth quarter of 2001 increased 56% to
$99.0 million, or $0.95 per share, compared with $63.8 million, or $0.61 per
share, for the fourth quarter of 2000.
Full year net income increased 51% to $342.2 million, or $3.30 per share,
compared with net income of $226.0 million, or $2.18 per share, for full year
2000. Net income, excluding net realized gains and other non-recurring items,
increased 51% to $314.1 million, or $3.03 per share, compared with $209.1
million, or $2.01 per share, for full year 2000.
"This was Anthem's first quarter as a public company and we are very pleased
with the results. We are confident that our strategy to grow profitable
enrollment while maintaining a disciplined focus on our business operations
should assure continued momentum in our future results," said Larry C.
Glasscock, president and chief executive officer of Anthem, Inc.
Consolidated Highlights
. Operating revenue increased 12% to $2.6 billion in the fourth quarter of
2001, compared with the fourth quarter of 2000. The increase was primarily
attributable to same store membership growth of approximately 10%, coupled
with disciplined pricing. For the full year 2001, operating revenue was
$10.1 billion, an increase of 18% over the prior year.
1
{PAGE}
. The benefit expense ratio increased 80 basis points, to 82.7% in the
fourth quarter of 2001, compared with the fourth quarter of 2000. For
full year 2001, the benefit expense ratio improved 20 basis points to
84.5%, compared with the same period in 2000. Days in claims payable
were 64.4 days at December 31, 2001, up 0.9 days from September 30,
2001.
. The administrative expense ratio improved 290 basis points to 20.1% in
the fourth quarter of 2001, compared with 23.0% in the same period of
2000. The improvement reflects growth in operating revenue and
membership gains without corresponding increases in administrative
expenses. For the full year 2001, the administrative expense ratio
improved 160 basis points to 19.6%.
. Operating gain was $107.1 million in the fourth quarter of 2001, an
increase of 67% compared with an operating gain of $64.2 million in
the same period of 2000. For the full year 2001, operating gain
increased 74% to $319.5 million, compared with $184.1 million for the
full year 2000. All operating segments contributed to the strong
earnings growth in 2001.
. The strength in operating gain and revenue growth resulted in a 4.1%
operating margin in the fourth quarter of 2001, which was the best
quarterly operating margin reported by Anthem in its history. For the
full year 2001, operating margin was 3.2%, a 100 basis point
improvement compared to the full year 2000.
Operating Segment Highlights
Midwest Segment Highlights
The Midwest segment is comprised of health benefit and related business for
members in Indiana, Kentucky and Ohio.
{TABLE}
{CAPTION}
------------------------------------------------------------------------------------------------------
Three Months Ended Twelve Months Ended
($ in Millions) December 31 December 31
-------------------------------- --------------------------------
2001 2000 Change 2001 2000 Change
---- ---- ------ ---- ---- ------
{S} {C} {C} {C} {C} {C} {C}
Operating Revenue $1,332.0 $1,166.8 14% $5,093.0 $4,460.5 14%
Operating Gain $42.2 $27.3 55% $161.5 $87.8 84%
Operating Margin 3.2% 2.3% 90 bp 3.2% 2.0% 120 bp
Membership (in 000s) 4,854 4,454* 9%
*Excludes 128,000 TRICARE members
--------------------------------------------------------------------------------------------------------
{/TABLE}
. Fourth quarter of 2001 operating revenue increased 14% compared to the
fourth quarter of 2000, primarily due to premium rate increases and
membership growth in Local Large Group and Small Group businesses.
. Operating gain was $42.2 million in the fourth quarter of 2001, an
increase of 55% compared to the same period in 2000. The improvement
was primarily due to revenue growth and enhanced operational
efficiency.
. On a same store basis, membership increased 9% in 2001. Membership
increases were primarily due to favorable retention and growth across
all customer segments.
2
301236
|
Anthem
As referenced in this Anthem, Inc. Reports Record Results for Fourth Quarter and Full Year 2001:
Anthem, Inc – {DOCUMENT}
{TYPE}EX-99
{SEQUENCE}3
{FILENAME}dex99.txt
{DESCRIPTION}PRESS RELEASE DATED FEBRUARY 6, 2002
{TEXT}
{PAGE}
EXHIBIT 99
news release Anthem, Inc .
120 Monument Circle
Indianapolis, IN 46204
Tel 317 488-6390
Fax 317 488-6460
[Anthem(R) LOGO APPEARS HERE]
Contacts: Investor Relations
_____________
Anthem, Inc – 317 488-6460
[Anthem(R) LOGO APPEARS HERE]
Contacts: Investor Relations
Tami Durle, 317-488-6390
Media
Lauren Green-Caldwell, 317-488-6321
Anthem, Inc . Reports Record Results for Fourth Quarter and Full Year 2001
. Earnings per share increased 56% in the fourth quarter and 51% for
_____________
Anthem, Inc – stock repurchase program
. EPS guidance for 2002 increased by $0.10, to $3.65 - $3.75 per share
Indianapolis, IN - February 6, 2002 - Anthem, Inc . (NYSE: ATH) today reported
that net income for the fourth quarter of 2001 increased 21% to $87.7 million,
or $0.85
_____________
Anthem, Inc – focus on our business operations
should assure continued momentum in our future results," said Larry C.
Glasscock, president and chief executive officer of Anthem, Inc .
Consolidated Highlights
. Operating revenue increased 12% to $2.6 billion in the fourth quarter of
2001, compared with the fourth quarter of
_____________
Anthem, Inc – 8-K
filed with the Securities and Exchange Commission, which attempt to advise
interested parties of the factors which affect Anthem's business.
Anthem, Inc .
Membership Summary
{TABLE}
{CAPTION}
-----------------------------------------------------------------------------------------------------------
% Change
-------------------------
(in Thousands) Dec. 31, Dec. 31, Sept. 30, Dec. 31, Sept. 30,
2001 2000 2001 2000 2001
-------------------------------------- -------------------------
{
_____________
dt 267006
| |
| Full Doc
| 2001 |
Crown Cork & Seal to Delist from the Paris Stock Exchange
Crown Cork & Seal to Delist from the Paris Stock Exchange (1K)
Doc #205437: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}EX-99
{SEQUENCE}3
{FILENAME}ex99-8knov01.txt
{DESCRIPTION}PRESS RELEASE ANNOUNCING PARIS DELISTING OF STOCK
{TEXT}
CROWN CORK & SEAL TO DELIST FROM THE PARIS STOCK EXCHANGE
---------------------------------------------------------
Philadelphia, PA - November 20, 2001. Crown Cork & Seal Company, Inc. (NYSE &
Paris Bourse: CCK) today announced that the Company intends to delist its shares
from the Paris Stock Exchange (Bourse) due to consistently low trading volumes.
This action will be effective on December 27, 2001. Crown has retained Societe
Generale as its agent in the delisting process.
Shareholders with shares through Euroclear France System will have the option to
sell their shares on the NYSE or to retain them for future trading on the NYSE.
The Company does not expect this action to have a material impact on trading
volumes on the NYSE.
Crown Cork & Seal is a leading supplier of packaging products to consumer
marketing companies around the world. World headquarters are located in
Philadelphia, Pennsylvania.
For more information, contact:
Timothy J. Donahue, Senior Vice President - Finance (215) 698-5088.
* * * end * * *
{/TEXT}
{/DOCUMENT}
205437
|
Crown Cork
As referenced in this Crown Cork & Seal to Delist from the Paris Stock Exchange:
crown cork – SEQUENCE}3
{FILENAME}ex99-8knov01.txt
{DESCRIPTION}PRESS RELEASE ANNOUNCING PARIS DELISTING OF STOCK
{TEXT}
CROWN CORK & SEAL TO DELIST FROM THE PARIS STOCK EXCHANGE
---------------------------------------------------------
Philadelphia, PA - November 20, 2001. Crown
crown cork – CROWN CORK & SEAL TO DELIST FROM THE PARIS STOCK EXCHANGE
---------------------------------------------------------
Philadelphia, PA - November 20, 2001. Crown Cork & Seal Company, Inc. (NYSE &
Paris Bourse: CCK) today announced that the Company intends to
crown cork – not expect this action to have a material impact on trading
volumes on the NYSE.
Crown Cork & Seal is a leading supplier of packaging products to consumer
marketing companies around the
dt 7328
| |
| Full Doc
| 2001 |
Titan/BTG Exchange Ratio Set
Titan/BTG Exchange Ratio Set (8K)
Doc #235638: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}425
{SEQUENCE}1
{FILENAME}a2064319z425.txt
{DESCRIPTION}425
{TEXT}
{Page}
Filed by The Titan Corporation
Pursuant to Rule 425 under the Securities Act of 1933
Subject Company: BTG, Inc.
Registration No. 333-70912
On November 20, 2001, The Titan Corporation issued the following press release
in connection with its pending acquisition of BTG, Inc.
--------------------------------------------------------------------------------
Titan Press Release
Titan/BTG Exchange Ratio Set
--------------------------------------------------------------------------------
SAN DIEGO, CA -November 20, 2001 - The Titan Corporation (NYSE: TTN) today
announced that it has fixed the exchange ratio for its acquisition by merger of
BTG, Inc. (Nasdaq: BTGI) at 0.53800. The exact exchange ratio was fixed based
upon $24.81, the average closing sales price for shares of Titan common stock
during the 15 consecutive trading days ending November 19, 2001.
Under the terms of the Agreement and Plan of Reorganization, dated as of
September 19, 2001, among Titan, BTG and T T Acquisition Corp., a newly formed
subsidiary of Titan, Titan will acquire all of the outstanding shares of BTG
common stock by means of a merger between TT and BTG, with BTG surviving the
merger as a wholly owned subsidiary of Titan. The merger is subject to the
satisfaction of customary closing conditions and the approval of BTG's
shareholders. The parties intend that the merger will be treated as a purchase
for accounting purposes and, with respect to the Titan stock issued to BTG's
shareholders, as a tax-free reorganization for tax purposes. The merger
agreement provides that BTG shareholders will receive 81% of the merger
consideration in shares of Titan common stock, and 19% in cash.
To preserve the tax treatment of the merger, if the aggregate value of the cash
to be paid to BTG shareholders were to otherwise exceed 20% of the total value
of the merger consideration to be paid to BTG shareholders calculated based on
the closing sales price of shares of Titan on the most recent trading day prior
to the effective time of the merger, Titan and BTG have agreed that the
aggregate amount of cash deliverable will be reduced to 19% of the total value
of the merger consideration paid to BTG shareholders calculated based on the
closing sales price of shares of Titan on the most recent trading day prior to
the effective time of the merger, and the aggregate number of shares of Titan
common stock deliverable at closing will be increased to equal 81% of such
value. On the date of the meeting of the BTG shareholders to be held on November
27, 2001, the final calculation of consideration to be paid in cash and Titan
shares to BTG shareholders will be determined.
ABOUT TITAN
Headquartered in San Diego, The Titan Corporation creates, builds and
launches technology-based businesses, offering innovative technical
solutions. Three of Titan's four core businesses develop and deploy
communications and information technology solutions and services. In
addition, Titan's SureBeam (NASDAQ: SURE) subsidiary
{Page}
markets the leading technology for the electronic pasteurization of food
products and Titan is continually identifying promising technologies suitable
for commercialization. Titan has 8,000 employees and annualized sales of
approximately $1.1 billion.
ABOUT BTG
Founded in 1982, BTG has been providing systems and solutions development,
analysis and consulting, integration and support services to U.S. defense and
intelligence customers as well as to other government customers for almost
twenty years. Areas of expertise include information collection and analysis,
warfare modeling and simulation, software and systems integration, network
design and architecture, and information and network security. Following the
completion of the transaction, BTG's nearly 2,000 employees will become part
of Titan Systems, Titan's government information technology subsidiary.
Titan has filed with the Securities and Exchange Commission a Registration
Statement on Form S-4 relating to the shares of its common stock that may be
issued in connection with the acquisition of BTG. The Prospectus forming a part
of that Registration Statement also includes BTG's Proxy Statement by which BTG
is soliciting proxies in connection with the special meeting of BTG shareholders
to be held on November 27, 2001 for consideration by the BTG shareholders of the
transaction. The Proxy Statement/Prospectus has been mailed to shareholders of
BTG. This document contains important information about the transaction.
Investors and security holders are urged to read these documents carefully.
Investors and security holders may obtain free copies of these documents through
the website maintained by the SEC at www.sec.gov. Free copies of these documents
may also be obtained from Titan by directing your request to Investor Relations
at www.titan.com or to The Titan Corporation, Investor Relations, 3033 Science
Park Road, San Diego, California 92121-1199, (858) 552-9400.
In addition to the Registration Statement and the Proxy Statement/Prospectus,
Titan and BTG file annual, quarterly and special reports, proxy statements
and other information with the SEC. You may read and copy any reports,
statements or other information filed by Titan or BTG at the SEC public
reference room at 450 Fifth Street, N.W., Washington, D.C. 20549 or at any of
the commission's other public reference rooms in New York, New York or
Chicago, Illinois. Please call the SEC at (800) SEC-0330 for further
information on the public reference rooms. Titan's and BTG's filings with the
SEC are also available to the public from the website maintained by the SEC
at www.sec.gov.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995: The statements contained in this release, which are not historical facts,
are forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Examples of such forward looking statements include the Company's belief that it
is in the strongest financial position in its history, that its technology-based
businesses will continue to grow or result in profitability, that its new
businesses can eventually be spun off as independent companies, that its
{Page}
government information technology business is stable and predictable and that it
will be able to capitalize on government funded research and development, and
that it expects half of its wireless revenues in the fourth quarter to come from
its service business. These statements are subject to risks and uncertainties
that could cause actual results to differ materially from those set forth in or
implied by forward-looking statements. These risks and uncertainties include the
risks associated with the Company's entry into new commercial businesses and new
markets such as the food pasteurization market that require the company to
develop demand for its product, its ability to execute its spin off strategy,
its ability to access the capital markets, dependence on continued funding of
U.S. Department of Defense and federal civilian agency programs, contract
termination risks, risks associated with acquiring other companies, including
integration risks, the risks of doing business in developing countries and
international markets including foreign currency risks, and other risks
described in the Company's Securities and Exchange Commission filings.
Media Contact:
Wil Williams, Vice President Corporate Communications
(858) 552-9724 or wwilliams@titan.com
Investor Relations Contact:
235638
|
Titan
As referenced in this Titan/BTG Exchange Ratio Set:
Titan Corp – DOCUMENT}
{TYPE}425
{SEQUENCE}1
{FILENAME}a2064319z425.txt
{DESCRIPTION}425
{TEXT}
{Page}
Filed by The Titan Corp oration
Pursuant to Rule 425 under the Securities Act of 1933
Subject Company: BTG, Inc.
Titan Corp – of 1933
Subject Company: BTG, Inc.
Registration No. 333-70912
On November 20, 2001, The Titan Corp oration issued the following press release
in connection with its pending acquisition of BTG, Inc.
--------------------------------------------------------------------------------
Titan Corp – Titan Press Release
Titan/BTG Exchange Ratio Set
--------------------------------------------------------------------------------
SAN DIEGO, CA -November 20, 2001 - The Titan Corp oration (NYSE: TTN) today
announced that it has fixed the exchange ratio for its acquisition
Titan Corp – Titan
shares to BTG shareholders will be determined.
ABOUT TITAN
Headquartered in San Diego, The Titan Corp oration creates, builds and
launches technology-based businesses, offering innovative technical
solutions. Three of Titan'
Titan Corp – Titan by directing your request to Investor Relations
at www.titan.com or to The Titan Corp oration, Investor Relations, 3033 Science
Park Road, San Diego, California 92121-1199, (858) 552-9400.
dt 47351
| |
| Full Doc
| 2001 |
Titan to Acquire BTG, Inc.
Titan to Acquire BTG, Inc. (10K)
Doc #235660: This document is immediately available for purchase, but does not have a preview available for viewing.
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>a2059733zex-99_1.txt
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<Page>
Exhibit 99.1
On September 20, 2001, The Titan Corporation issued the following press release
relating to its proposed acquisition of BTG, Inc.:
------------------------------------------------------------------------
Titan to Acquire BTG, Inc.
------------------------------------------------------------------------
SAN DIEGO, September 20, 2001 -- The Titan Corporation (NYSE: TTN) today
announced that it has entered into a definitive agreement to acquire BTG, Inc.
(Nasdaq: BTGI), a provider of information technology solutions and services
primarily to the U.S. military and other government agencies for $13.35 per BTG
share or approximately $114.9 million in Titan common stock and $27.0 million in
cash. The purchase price, which includes the assumption of approximately $32
million in debt, represents approximately .68x BTG's calendar 2001 expected
revenues of $255 million. The transaction is expected to close by the end of
2001 and will be accretive to Titan's earnings in 2002. Credit Suisse First
Boston acted as a financial advisor to Titan on the transaction.
Founded in 1982, BTG has been providing systems and solutions development,
analysis and consulting, integration and support services to U.S. defense and
intelligence customers as well as to other government customers for almost
twenty years. Areas of expertise include information collection and analysis,
warfare modeling and simulation, software and systems integration, network
design and architecture, and information and network security. Following the
completion of the transaction, BTG's nearly 2000 employees will become part of
Titan Systems, Titan's government information technology subsidiary.
"BTG's core competency in providing government information technology solutions
and services is highly complementary to our existing operations at Titan
Systems. While our capabilities are similar, there is little overlap in our
customer base. As a result, this acquisition will further expand Titan Systems'
reach into the U.S. military and intelligence operations market and provide us
with new opportunities to aggressively pursue new business. In addition, the
synergies achieved by combining BTG with Titan Systems should allow us to
significantly improve BTG's operating margins, creating value for both Titan and
BTG shareholders," said Eric M. DeMarco, Executive Vice President and Chief
Operating Officer of Titan.
"With the acquisition of BTG, Titan Systems should approach nearly $1.3 billion
in revenues next year, with approximately $1 billion of that revenue generated
by contracts for government information technology services and the remainder
comprised of government product sales and government funded research and
development projects. As with each of our subsidiaries, our
<Page>
goal for Titan Systems has been to create a company well positioned in its key
market for long-term growth and capable of becoming an independent stand alone
company. With $1 billion in government information technology service revenue,
we believe we have achieved the goal that we set out to accomplish only a few
years ago," said Gene W. Ray, Chairman, President and CEO of Titan.
Under the terms of the definitive agreement, a newly formed subsidiary of Titan
will be merged with and into BTG, with BTG surviving the merger as a wholly
owned subsidiary of Titan. All of the outstanding shares of BTG stock will be
exchanged for Titan stock and cash pursuant to the terms of the definitive
agreement, as set forth below. The merger is subject to the satisfaction of
customary closing conditions, the approval of BTG's shareholders and the
approval of Titan's lenders. The parties intend that the merger will be treated
as a purchase for accounting purposes and, with respect to the Titan stock
issued to BTG's shareholders, as a tax-free reorganization for tax purposes.
The total consideration, which is to paid in approximately 81% Titan stock and
19% cash, may change if Titan's stock falls below $17.75. If the 15 day average
closing sales price for Titan's common stock (ending 5 trading days prior to the
date of BTG's shareholders' meeting) is between $16.15 and $17.74, then Titan
will issue approximately 6.5 million shares of Titan common stock to the BTG
securityholders and cash in an amount equal to approximately 19% of the total
consideration. If the average Titan closing price is less than $16.15, then
Titan will issue shares of Titan common stock having an aggregate value of
approximately $104.6 million to the BTG securityholders and cash in an amount
equal to approximately 19% of the total consideration.
The foregoing summary is a general description of certain pricing and related
terms contained in the definitive agreement for the transaction, and is
qualified in its entirety by reference to the definitive agreement, a copy of
which will be filed by Titan with the Securities and Exchange Commission.
Titan intends to file a Registration Statement on Form S-4 and BTG plans to file
a Proxy Statement, with the Securities and Exchange Commission in connection
with the transaction. Titan and BTG expect to mail a Proxy Statement/Prospectus
to stockholders of BTG. These documents contain important information about the
transaction. Investors and security holders are urged to read these documents
carefully when they are available. Investors and security holders will be able
to obtain free copies of these documents through the website maintained by the
U.S. Securities and Exchange Commission at www.sec.gov.
Headquartered in San Diego, The Titan Corporation creates, builds and launches
technology-based businesses, offering innovative technical solutions. Three of
Titan's four core businesses develop and deploy communications and information
technology solutions and services. In addition, Titan's SureBeam (Nasdaq: SURE)
subsidiary markets the leading technology for the electronic pasteurization of
food products and Titan is continually identifying promising technologies
suitable for commercialization. The company has 7,800 employees and annualized
sales of approximately $1.1 billion.
<Page>
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995: The statements contained in this release, which are not historical facts,
are forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Examples of such forward looking statements include the Company's belief that
the acquisition of BTG will allow Titan to expand its presence with government
customers and that BTG has expertise in areas that are highly complementary to
Titan's internal capabilities and that their operations can be easily integrated
into Titan. These statements are subject to uncertainties that could cause
actual results to differ materially from those set forth in or implied by
forward-looking statements. These risks and uncertainties include contract
termination risks, risks associated with acquiring other companies, including
integration risks, the risks of doing business in developing countries and
international markets including foreign currency risks, and other risks
described in the Company's Securities and Exchange Commission filings.
Titan and BTG will file with the Securities and Exchange Commission a proxy
statement/prospectus and other documents regarding the proposed business
combination transaction referred to in the foregoing information. INVESTORS AND
SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS WHEN IT
BECOMES AVAILABLE AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, BECAUSE
THEY WILL CONTAIN IMPORTANT INFORMATION. A definitive proxy statement/prospectus
will be sent to security holders of BTG seeking their approval of the
transaction. Investors and security holders may obtain a free copy of the
definitive proxy statement/prospectus (when they are available) and other
documents filed by Titan and BTG with the Commission at the Commission's web
235660
|
Titan
As referenced in this Titan to Acquire BTG, Inc.:
Titan Corp – 1
<TEXT>
<Page>
Exhibit 99.1
On September 20, 2001, The Titan Corp oration issued the following press release
relating to its proposed acquisition of BTG, Inc.:
------------------------------------------------------------------------
Titan
Titan Corp – acquisition of BTG, Inc.:
------------------------------------------------------------------------
Titan to Acquire BTG, Inc.
------------------------------------------------------------------------
SAN DIEGO, September 20, 2001 -- The Titan Corp oration (NYSE: TTN) today
announced that it has entered into a definitive agreement to acquire
Titan Corp – U.S. Securities and Exchange Commission at www.sec.gov.
Headquartered in San Diego, The Titan Corp oration creates, builds and launches
technology-based businesses, offering innovative technical solutions. Three of
Titan'
Titan Corp – 3877 Fairfax Ridge Road, Fairfax, VA 22030, Attn: Investor Relations (703)
383-8140 or The Titan Corp oration, 3033 Science Park Road, San Diego, CA 92121,
Attn: Investor Relations (858) 552-9400.
dt 47682
| |
| Full Doc
| 2001 |
Titan Completes Exchange Offer For Datron Systems Incorporated
Titan Completes Exchange Offer For Datron Systems Incorporated (5K)
Doc #235688: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}425
{SEQUENCE}1
{FILENAME}a2056015z425.txt
{DESCRIPTION}425
{TEXT}
{Page}
Document is copied.
Filed by Titan Corporation pursuant to Rule 425 under the Securities Act of
1933.
Subject Company: Datron Systems Inc. Commission file No.: 333-64768
TITAN COMPLETES EXCHANGE OFFER
FOR DATRON SYSTEMS INCORPORATED
SAN DIEGO, CA - AUGUST 6, 2001 - THE TITAN CORPORATION (NYSE: TTN)
today announced the expiration of the exchange offer by its wholly owned
subsidiary, Gem Acquisition Corp., for all of the outstanding shares of Datron
Systems Incorporated (Nasdaq: DTSI) common stock. The offer expired at midnight
New York time on Friday, August 3, 2001. All shares validly tendered (and not
properly withdrawn) prior to the expiration have been accepted for exchange and
will be exchanged promptly for Titan shares and for cash for fractional shares.
Approximately 2,019,260 shares were tendered (including through notices
of guaranteed delivery) in the exchange offer prior to its expiration, which
constitutes approximately 71.9% percent of the total number of outstanding
shares of common stock of Datron. The pending merger of Datron and Gem
Acquisition Corp., Titan's merger subsidiary, will be completed as soon as
practicable subject to the terms of the Agreement and Plan of Merger and
Reorganization among Datron, Gem and Titan and subject to applicable legal
requirements. Once the pending merger becomes effective, Datron will become a
wholly owned subsidiary of Titan. The information agent for the exchange offer
is D.F. King & Co., Inc., 77 Water Street, 20th Floor, New York, NY 10005,
telephone 800-848-3409.
Headquartered in San Diego, The Titan Corporation creates, builds and
launches technology-based businesses, offering innovative technical solutions.
Three of Titan's four core businesses develop and deploy communications and
information technology solutions and services. In addition, Titan's SureBeam
(Nasdaq: SURE) www.surebeamcorp.com subsidiary markets the leading technology
for the electronic pasteurization of food products and Titan is continually
identifying promising technologies suitable for commercialization.
Founded in 1969 as a defense contractor, Datron has pioneered the
development of antennas to track airborne rockets, missiles, weaponry, and
spacecraft. Datron has developed expertise in remote sensing, image processing,
satellite tracking and antenna manufacturing with products including remote
sensing satellite earth stations, image processing software, tracking systems,
and voice and data communication radio products.
A registration statement relating to these securities has been filed
with and declared effective by the Securities and Exchange Commission. In
addition, The Titan Corporation has filed a Schedule TO, and Datron Systems
Incorporated has filed a Solicitation/Recommendation Statement on Schedule 14D-9
with the Securities and Exchange Commission in connection with the transaction.
The Prospectus, Schedule 14D-9 and related tender offer materials have been
mailed to stockholders of Datron. These documents contain important information
about the transaction. Investors and security holders are urged to read these
documents carefully. Investors and security holders may obtain free copies of
these documents through the website maintained by the U.S. Securities and
Exchange Commission at www.sec.gov. The registration statement may be obtained
free at the SEC's web site at www.sec.gov. The registration statement may also
be obtained for free from Titan by directing your request to Investor Relations
at www.titan.com or to The Titan Corporation, Investor Relations, 3033 Science
Park Road, San Diego, California 92121-1199, Attn: Rochelle R. Bold, Vice
President, Investor Relations, telephone number: (858) 552-9500. Free copies of
these documents may also be obtained from Datron Systems
{Page}
Incorporated by directing a request to the Investor Relations section of
Datron's website at www.dtsi.com or by mail to Datron Systems Incorporated, 3030
Enterprise Court, Vista, CA 92083, attention, Investor Relations.
In addition to the Schedule TO, prospectus and Schedule 14D-9, Titan and Datron
file annual, quarterly and special reports, proxy statements and other
information with the Securities and Exchange Commission. You may read and copy
any reports, statements or other information filed by Titan or Datron at the SEC
public reference room at 450 Fifth Street, N.W., Washington, D.C. 20549 or at
any of the commission's other public reference rooms in New York, N.Y. and
Chicago, Ill. Please call the Securities and Exchange Commission at 800-SEC-0330
for further information on the public reference rooms. Titan's and Datron's
filings with the Securities and Exchange Commission are also available to the
public from commercial document-retrieval services and at the website maintained
by the commission at http://www.sec.gov.
{/TEXT}
{/DOCUMENT}
235688
|
Titan
As referenced in this Titan Completes Exchange Offer For Datron Systems Incorporated:
Titan Corp – 425
{SEQUENCE}1
{FILENAME}a2056015z425.txt
{DESCRIPTION}425
{TEXT}
{Page}
Document is copied.
Filed by Titan Corp oration pursuant to Rule 425 under the Securities Act of
1933.
Subject Company: Datron Systems
TITAN CORP – TITAN COMPLETES EXCHANGE OFFER
FOR DATRON SYSTEMS INCORPORATED
SAN DIEGO, CA - AUGUST 6, 2001 - THE TITAN CORP ORATION (NYSE: TTN)
today announced the expiration of the exchange offer by its wholly owned
Titan Corp – 20th Floor, New York, NY 10005,
telephone 800-848-3409.
Headquartered in San Diego, The Titan Corp oration creates, builds and
launches technology-based businesses, offering innovative technical solutions.
Three of Titan'
Titan Corp – been filed
with and declared effective by the Securities and Exchange Commission. In
addition, The Titan Corp oration has filed a Schedule TO, and Datron Systems
Incorporated has filed a Solicitation/Recommendation
Titan Corp – Titan by directing your request to Investor Relations
at www.titan.com or to The Titan Corp oration, Investor Relations, 3033 Science
Park Road, San Diego, California 92121-1199, Attn: Rochelle R.
dt 47375
| |
| Full Doc
| 2001 |
Titan Fixes Titan Common Stock Price for Exchange Offer For Datron Systems Incorporated
Titan Fixes Titan Common Stock Price for Exchange Offer For Datron Systems Incorporated (6K)
Doc #235698: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}425
{SEQUENCE}1
{FILENAME}a2055461z425.txt
{DESCRIPTION}425
{TEXT}
{Page}
Document is copied.
Filed by Titan Corporation pursuant to Rule 425 under the Securities Act of
1933.
Subject Company: Datron Systems Inc. Commission file No.: 333-64768
TITAN FIXES TITAN COMMON STOCK PRICE FOR EXCHANGE OFFER
FOR DATRON SYSTEMS INCORPORATED
SAN DIEGO, JULY 30, 2001/PRNEWSWIRE/ - THE TITAN CORPORATION (NYSE:
TTN) today announced that it has fixed the Titan common stock price for use
in computing the exchange ratio for its exchange offer to acquire all the
outstanding shares of common stock of Datron Systems Incorporated (Nasdaq:
DTSI). The exact exchange ratio will be computed based upon $19.54, the
average closing sales price for shares of Titan common stock during the
10-day trading period ending on July 27, 2001.
The offer is being made through Gem Acquisition Corp., a wholly-owned
subsidiary of Titan, pursuant to the Agreement and Plan of Merger, dated as of
June 24, 2001, among Titan, Datron and Gem Acquisition Corp. It is conditioned,
among other things, upon necessary regulatory approvals being obtained and at
least a majority of the total number of outstanding shares of Datron being
tendered and not withdrawn as of the date the offer expires. The offer commenced
on July 9, 2001 and is scheduled to expire at midnight New York City time, on
August 3, 2001, unless extended.
Under the terms of the merger agreement, the exchange ratio (rounded
to the fifth decimal point) is determined by dividing (1) $51,226,912 divided
by the number of shares of Datron common stock outstanding as of, or issuable
upon the exercise of stock options or other rights to acquire shares of
Datron common stock outstanding as of, the date that shares of Datron common
stock are accepted for payment pursuant to the exchange offer, by (2) $19.54.
As of July 27, 2001, the number of shares of Datron common stock outstanding,
or issuable upon the exercise of stock options or other rights to acquire
shares of Datron common stock, was 3,200,734. Computed as of July 27, 2001,
the exchange ratio in the offer was 0.81883, and Titan does not expect the
exchange ratio to be materially different at the closing of the exchange
offer.
A registration statement related to these securities, as amended,
has been filed with the Securities and Exchange Commission. The registration
statement may be obtained free at the SEC's web site at www.sec.gov. The
registration statement may also be obtained for free from Titan by directing
your request to Investor Relations at www.titan.com or to The Titan
Corporation, Investor Relations, 3033 Science Park Road, San Diego,
California 92121-1199, Attn: Rochelle R. Bold, Vice President, Investor
Relations, (858) 552-9400.
The information agent for the offer is D.F. King & Co., Inc., 77
Water Street, 20th Floor, New York, New York 10005, (800) 848-3409.
Headquartered in San Diego, The Titan Corporation creates, builds and
launches technology-based businesses, offering innovative technical solutions.
Three of Titan's four core businesses develop and deploy communications and
information technology solutions and services. In addition, Titan's SureBeam
(Nasdaq: SURE) www.surebeamcorp.com subsidiary markets the leading technology
for the electronic pasteurization of food products and Titan is continually
identifying promising technologies suitable for commercialization.
1.
{Page}
Founded in 1969 as a defense contractor, Datron has pioneered the
development of antennas to track airborne rockets, missiles, weaponry, and
spacecraft. Datron has developed expertise in remote sensing, image processing,
satellite tracking and antenna manufacturing with products including remote
sensing satellite earth stations, image processing software, tracking systems,
and voice and data communication radio products.
A registration statement relating to these securities, as amended, has
been filed with the Securities and Exchange Commission. In addition, The Titan
Corporation has filed a Schedule TO, and Datron Systems Incorporated has filed a
Solicitation/Recommendation Statement on Schedule 14D-9 with the Securities and
Exchange Commission in connection with the transaction. The Prospectus, Schedule
14D-9 and related tender offer materials have been mailed to stockholders of
Datron. These documents contain important information about the transaction.
Investors and security holders are urged to read these documents carefully.
Investors and security holders may obtain free copies of these documents through
the website maintained by the U.S. Securities and Exchange Commission at
www.sec.gov. Free copies of these documents may also be obtained from Datron
Systems Incorporated by directing a request to the Investor Relations section of
Datron's website at www.dtsi.com or by mail to Datron Systems Incorporated, 3030
Enterprise Court, Vista, CA 92083, attn: Investor Relations.
In addition to the registration statement, Schedule TO, Prospectus
and Schedule 14D-9, Titan and Datron file annual, quarterly and special
reports, proxy statements and other information with the Securities and
Exchange Commission. You may read and copy any reports, statements or other
information filed by Titan or Datron at the SEC public reference room at 450
Fifth Street, N.W., Washington, D.C. 20549 or at any of the commission's
other public reference rooms in New York, New York or Chicago, Illinois.
Please call the Securities and Exchange Commission at (800) SEC-0330 for
further information on the public reference rooms. Titan's and Datron's
filings with the Securities and Exchange Commission are also available to the
public from commercial document-retrieval services and at the website
maintained by the commission at http://www.sec.gov.
2.
{/TEXT}
{/DOCUMENT}
235698
|
Titan
As referenced in this Titan Fixes Titan Common Stock Price for Exchange Offer For Datron Systems Incorporated:
Titan Corp – 425
{SEQUENCE}1
{FILENAME}a2055461z425.txt
{DESCRIPTION}425
{TEXT}
{Page}
Document is copied.
Filed by Titan Corp oration pursuant to Rule 425 under the Securities Act of
1933.
Subject Company: Datron Systems
TITAN CORP – PRICE FOR EXCHANGE OFFER
FOR DATRON SYSTEMS INCORPORATED
SAN DIEGO, JULY 30, 2001/PRNEWSWIRE/ - THE TITAN CORP ORATION (NYSE:
TTN) today announced that it has fixed the Titan common stock price for
Titan
Corp – Titan by directing
your request to Investor Relations at www.titan.com or to The Titan
Corp oration, Investor Relations, 3033 Science Park Road, San Diego,
California 92121-1199, Attn: Rochelle R.
Titan Corp – 20th Floor, New York, New York 10005, (800) 848-3409.
Headquartered in San Diego, The Titan Corp oration creates, builds and
launches technology-based businesses, offering innovative technical solutions.
Three of Titan'
Titan
Corp – securities, as amended, has
been filed with the Securities and Exchange Commission. In addition, The Titan
Corp oration has filed a Schedule TO, and Datron Systems Incorporated has filed a
Solicitation/Recommendation
dt 47383
| |
Preview
Full Doc
| 2001 |
GM's Hughes Electronics to Merge with Echostar Communications
GM's Hughes Electronics to Merge with Echostar Communications (21K)
Doc #239265: Click preview link for longer preview.
{DOCUMENT}
{TYPE}EX-99.1
{SEQUENCE}3
{FILENAME}dex991.txt
{DESCRIPTION}PRESS RELEASE DATED 10-28-2001
{TEXT}
{PAGE}
Exhibit 99.1
For Release: Sunday, Oct. 28, 2001 Contacts:
---------
GM: Toni Simonetti 212-418-6380
Hughes: George Jamison 310-662-9986
EchoStar: Judianne Atencio 303-723-2010
GM'S HUGHES ELECTRONICS TO MERGE WITH ECHOSTAR COMMUNICATIONS
. Stockholders and Consumers Benefit As Combined Hughes-EchoStar
Provides Meaningful Competitor To Cable TV Companies
NEW YORK -- General Motors Corp. and its subsidiary Hughes Electronics
(NYSE: GM, GMH) together with EchoStar Communications Corporation (NASDAQ:
DISH), today announced the signing of definitive agreements that provide for the
spin-off of Hughes from GM and the merger of Hughes with EchoStar.
The combined company would use the EchoStar name and adopt the DIRECTV
brand for its services and related products. The merger would create the
nation's second-largest pay television platform with more than 16.7 million
subscribers, of which 1.8 million subscribers are National Rural
Telecommunications Cooperative (NRTC) and affiliates, and 14.9 million
subscribers are owned-and-operated by the combined company. Cable TV companies
presently control more than 80 percent of the U.S. pay television market, while
a combined EchoStar-Hughes would provide service to about 17 percent of the
market.
The spin-off of Hughes from GM would result in current holders of Class H
common stock receiving one share of new Hughes Class C common stock in exchange
for each share of Class H stock held prior to the spin-off. The merger of Hughes
and EchoStar would result in Hughes being the surviving entity and taking the
name EchoStar Communications Corp. Holders of Class A EchoStar common stock
prior to the merger would receive 1.3699 shares of the new EchoStar in exchange
for each share of Class A EchoStar common stock held prior to the merger. Based
on the closing price of EchoStar common stock of $25.26 on Oct. 26, 2001, the
transaction would provide a value of approximately $18.44 per GMH share,
representing a 20-percent premium. As of Oct. 26, 2001, the implied market
capitalization of Hughes was approximately $21.3 billion and the market
capitalization of EchoStar was approximately $12.1 billion.
The transaction is expected to require approximately $5.5 billion of total
financing, which EchoStar expects to fund in the capital markets prior to
closing. Completion of this financing has been backstopped by a bridge
commitment of approximately $2.75 billion from Deutsche Bank, and a bridge
commitment of approximately $2.75 billion from General Motors, the latter of
which the parties plan to replace with a commitment from one or more other
leading financial institutions in the near future. The GM bridge commitment is
secured by a pledge of $2.75 billion of EchoStar stock held by a trust
controlled by EchoStar Chairman and Chief Executive Officer Charles Ergen.
The transaction is subject to a number of conditions, including approval by
a majority of each class of GM shareholders - GM $1-2/3 and GM Class H - voting
both separately as distinct classes, and also together as a single class.
Approval of the majority of EchoStar's voting shares has already been given by
written consent. The proposed transaction also is subject to regulatory
clearance under the Hart-Scott-Rodino Act and approval by the Federal
Communications Commission. The transaction is also contingent upon the receipt
of a favorable ruling from the Internal Revenue Service that the separation of
{PAGE}
Hughes from GM will qualify as a tax-free spin-off for U.S. Federal Income Tax
purposes. The transaction is currently expected to close in the second half of
2002.
"This transaction provides significant benefits to Hughes, EchoStar,
millions of present and future DIRECTV customers, and shareholders of both GM
and EchoStar," said GM President and Chief Executive Officer Rick Wagoner.
"We've said all along that we wanted to structure an agreement that would
provide continued strong growth at Hughes and maximum value for both GM and GM
Class H shareholders. This transaction achieves these objectives."
Strong Growth Prospects and Significant Synergies
"This is an extremely compelling combination for GM, GMH and EchoStar
shareholders," Ergen said. "The combination of EchoStar and Hughes is expected
to generate very substantial synergies utilizing the advantages of
direct-broadcast satellite television, cost savings from the elimination of
costly duplicate satellite bandwidth and infrastructure, and strong management
offering more effective fundamental business practices. The new company would
also have enhanced scale to compete more effectively against the dominant U.S.
cable and broadband providers - a critical factor given increasing consolidation
in the cable industry."
"U.S. consumers also would benefit from the combined company's ability to
increase significantly the number of markets served with local channels via
satellite, provide additional channel offerings, increase high-definition TV
(HDTV) offerings and accelerate the introduction of next-generation high-speed
Internet services," Ergen continued. "Together, EchoStar's DISH Network and
Hughes' DIRECTV also can provide a range of services that would bridge the
`digital divide' - providing high-speed broadband solutions to consumers and
businesses. Importantly, these services would be available in rural areas
otherwise far from the information superhighway at rates which the company is
prepared to assure regulators would be competitive."
"Hughes and its operating companies would be well positioned to thrive as
part of this merged company," said Jack A. Shaw, chief executive officer of
Hughes. "DIRECTV would enjoy significant cost efficiencies and better use of its
assets. Hughes Network Systems would play a key strategic part in the growth of
satellite-delivered broadband. PanAmSat would have continued growth
opportunities. And DIRECTV Latin America would benefit from the synergies of the
larger combined company," Shaw said.
The new company, which would retain the EchoStar name but would use the
DIRECTV brand for consumer offerings, would be based in Littleton, Colo., and
would employ approximately 20,000 people and serve more than approximately 14.9
million direct-broadcast satellite TV customers. EchoStar and Hughes have
pledged that the merger would not cause disruption of service or additional
expense to existing customers of either DIRECTV or DISH Network service.
The new EchoStar would be led by Ergen as chairman and chief executive
officer. The board of directors would consist of nine members, five of whom
would be independent directors.
Ergen added, "I think it is significant that EchoStar and Hughes have
agreed to a fair and balanced process for identifying the most qualified people
from both companies in order to select the best person for every job, regardless
where they worked prior to the merger. This is a key provision that Hughes
management felt strongly about and to which EchoStar readily agreed."
{PAGE}
A transition team made up of Shaw and DIRECTV Chairman and CEO Eddy
Hartenstein from Hughes, as well as Ergen and EchoStar President Michael Dugan
will assure a smoother and orderly process.
Significant Proceeds for GM
As part of the transaction, General Motors would receive up to $4.2 billion
in cash for redemption of part of its economic interest in Hughes. Pro forma for
the cash redemption (assuming illustratively a price of $18.44 based on the
implied deal value), GM Class H shareholder would own approximately 53 percent
of the combined company, EchoStar's shareholders would own approximately 36
percent, and GM would own approximately 11 percent. In addition, prior to the
239265
|
EchoStar
As referenced in this GM's Hughes Electronics to Merge with Echostar Communications:
EchoStar Communications Corp – EchoStar
Provides Meaningful Competitor To Cable TV Companies
NEW YORK -- General Motors Corp. and its subsidiary Hughes Electronics
(NYSE: GM, GMH) together with EchoStar Communications Corp oration (NASDAQ:
DISH), today announced the signing of definitive agreements that provide for the
spin-off of Hughes from GM and the merger
_____________
EchoStar Communications Corp – prior to the spin-off. The merger of Hughes
and EchoStar would result in Hughes being the surviving entity and taking the
name EchoStar Communications Corp . Holders of Class A EchoStar common stock
prior to the merger would receive 1.3699 shares of the new EchoStar in exchange
_____________
EchoStar Communications Corp – urged to read the
proxy statement/prospectus when it becomes available because it will contain
important information about GM, Hughes and the transaction.
EchoStar Communications Corp . and its DISH Network provide state-of-the-art
direct-broadcast satellite TV service that is capable of offering over 500
channels
_____________
EchoStar Communications Corp – any future results expressed or implied by such
forward-looking statements. The factors that could cause actual results of
General Motors Corp. ("GM"), EchoStar Communications Corp oration ("EchoStar"),
Hughes Electronics Corp. ("Hughes"), or a combined EchoStar and Hughes to differ
materially, many of which are beyond the control of
_____________
dt 213744
;
General Motors
As referenced in this GM's Hughes Electronics to Merge with Echostar Communications:
General Motors Corp – Consumers Benefit As Combined Hughes-EchoStar
Provides Meaningful Competitor To Cable TV Companies
NEW YORK -- General Motors Corp . and its subsidiary Hughes Electronics
(NYSE: GM, GMH) together with EchoStar Communications Corporation (NASDAQ:
General Motors Corp – or implied by such
forward-looking statements. The factors that could cause actual results of
General Motors Corp . ("GM"), EchoStar Communications Corporation ("EchoStar"),
Hughes Electronics Corp. ("Hughes"), or a combined EchoStar and
dt 65787
;
|
Hughes
As referenced in this GM's Hughes Electronics to Merge with Echostar Communications:
Hughes Electronics Corp – of digital television entertainment,
broadband services, satellite-based private business networks and global video
and data broadcasting.
Hughes Network Systems, a unit of Hughes Electronics Corp oration, is the
world's leading provider of broadband satellite network solutions for businesses
and consumers, with over 400,000 one- and two-
_____________
Hughes Electronics Corp – television service
provider with more than 10 million customers. DIRECTV and the Cyclone Design
logo are trademarks of DIRECTV, Inc., a unit of Hughes Electronics Corp oration.
Visit DIRECTV on the World Wide Web at DIRECTV.com.
General Motors, the world's largest vehicle manufacturer, designs, builds
and markets
_____________
Hughes Electronics Corp – or implied by such
forward-looking statements. The factors that could cause actual results of
General Motors Corp. ("GM"), EchoStar Communications Corporation ("EchoStar"),
Hughes Electronics Corp . ("Hughes"), or a combined EchoStar and Hughes to differ
materially, many of which are beyond the control of EchoStar, Hughes or GM
_____________
dt 213739
|
| Full Doc
| 2001 |
Ford Motor Company's November U.S. Sales Increased 4.4%
Ford Motor Company's November U.S. Sales Increased 4.4% (2K)
Doc #240267: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}EX-20
{SEQUENCE}3
{FILENAME}e120301ex20.txt
{TEXT}
Exhibit 20
NEWS
Contact:
George Pipas
1.313.323.9216
gpipas@ford.com
Media Information Center
1.800.665.1515 or
1.313.621.0504
media@ford.com
Go to http://media.ford.com
for news releases and
high-resolution photographs
IMMEDIATE RELEASE
-----------------
FORD MOTOR COMPANY'S NOVEMBER U.S. SALES INCREASED 4.4%
FORD F-SERIES AND EXPLORER PACE RECORD TRUCK SALES; NEW PRODUCTS HELP LIFT
JAGUAR AND LAND ROVER TO NEW SALES RECORDS
DEARBORN, MI, December 3, 2001 - U.S. customers purchased or leased 313,906 cars
and trucks from Ford, Mercury, Lincoln, Jaguar, Volvo, and Land Rover dealers in
November, up 4.4 percent compared with a year ago.
Ford trucks, America's best-selling brand of trucks for 16 years in a row,
achieved record November sales (188,667) paced by the F-Series truck and
Explorer SUV. F-Series, America's best-selling truck for 25 years in a row, set
a November sales record of 74,039, up 11.6 percent compared with a year ago.
Explorer, America's best-selling sport utility for 11 years in a row, posted
near-record sales of 36,939, up 10.5 percent from a year ago. The Ford Escape
and Ford Windstar also set November sales records.
Jaguar dealers reported an all-time sales record for any month as 5,016 U.S.
customers took delivery of a new Jaguar, up 38.3 percent compared with a year
ago. The previous any-month record (4,946) was set December 1999 and the
previous November record (3,628) was set last year. Jaguar's new all-wheel drive
X-TYPE led the way with sales of 2,413.
{PAGE}
-2-
Land Rover dealers reported record November sales as the first U.S. customers
took delivery of the all-new Freelander compact sport utility vehicle. Land
Rover sales totaled 2,634, up 15.6 percent. The previous record (2,279) was set
last year. Freelander sales were 168. An all-new Range Rover, Land Rover's
ultimate four-wheel-drive offering, debuts next spring.
Lincoln Mercury dealers reported November sales of 37,214, up 9.2 percent
compared with a year ago. Mercury brand cars and trucks paced the increase as
sales climbed 23.2 percent. The Grand Marquis (up 36.3 percent) and all-new
Mountaineer (up 88.9 percent) accounted for most of the increase in Mercury
sales. Lincoln sales declined 10.5 percent.
Volvo dealers reported November sales of 7,465, down 25.6 percent from a year
ago.
North American Production
-------------------------
Ford Motor Company plans to maintain its previously-announced fourth quarter
North American production at 965,000 vehicles. The company's initial forecast of
first quarter 2002 North production is 980,000 vehicles.
{/TEXT}
{/DOCUMENT}
240267
|
Ford Motor
As referenced in this Ford Motor Company's November U.S. Sales Increased 4.4%:
FORD MOTOR CO – Go to http://media.ford.com
for news releases and
high-resolution photographs
IMMEDIATE RELEASE
-----------------
FORD MOTOR CO MPANY'S NOVEMBER U.S. SALES INCREASED 4.4%
FORD F-SERIES AND EXPLORER PACE
Ford Motor Co – sales of 7,465, down 25.6 percent from a year
ago.
North American Production
-------------------------
Ford Motor Co mpany plans to maintain its previously-announced fourth quarter
North American production at 965,000
dt 66376
| |
| Full Doc
| 2001 |
Ford Motor Company Breaks 24-Year- Old Record as U.S. Sales Soar 34.4%
Ford Motor Company Breaks 24-Year- Old Record as U.S. Sales Soar 34.4% (2K)
Doc #240276: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}EX-20
{SEQUENCE}3
{FILENAME}e110101ex20.txt
{TEXT}
Exhibit 20
NEWS
Contact:
George Pipas
1.313.323.9216
gpipas@ford.com
Media Information Center
1.800.665.1515 or
1.313.621.0504
media@ford.com
Go to http://media.ford.com
for news releases and
high-resolution photographs
IMMEDIATE RELEASE
FORD MOTOR COMPANY BREAKS 24-YEAR- OLD RECORD AS U.S. SALES SOAR 34.4%
AMERICA'S BEST-SELLING TRUCK SHATTERS ALL-TIME RECORD WITH OCTOBER SALES OF
102,424
DEARBORN, MI, November 1, 2001 - U.S. customers purchased or leased 418,243 cars
and trucks from Ford, Mercury, Lincoln, Jaguar, Volvo, and Land Rover dealers in
October, soaring 34.4 percent higher than a year ago, and setting a new October
sales record. The previous record (375,797) was set in 1977.
Ford F-Series, America's best-selling truck since 1977, achieved an all-time
truck sales record for any month as October sales reached the unimaginable total
of 102,424. The F-Series set the previous record (91,481) in June 2001. F-Series
sales were 51.2 percent higher than a year ago.
Ford, America's best-selling brand of cars and trucks for 16 years in a row, set
a new October sales record (348,577) as sales climbed 35.8 percent. In addition
to F-Series' record-setting performance, Ford dealers reported any-month record
sales for the Ford Focus (33,439) and the Ford Escape (24,402) and an October
sales record for the Ford Explorer (44,640). Explorer sales were 45.2 percent
higher than a year ago. Ford Mustang, America's legendary pony car, achieved a
92.4 percent sales increase. In addition, Ford dealers delivered 1,315 Ford
Thunderbirds to U.S. customers in October.
{PAGE}
-2-
Mercury dealers reported October sales of 37,519, up 60.3 percent compared with
a year ago. Mercury Mountaineer (4,674) set a new October sales record as sales
climbed 33.9 percent. Sales for the Mercury Grand Marquis surged 106.3 percent,
Mercury Cougar sales rose 44.0 percent, Mercury Sable was up 36.7 percent, and
Mercury Villager sales were 75.2 percent higher than a year ago.
Lincoln dealers reported October sales of 15,302, up 4.2 percent compared with a
year ago. Lincoln LS set an October sales record (3,976). The Lincoln Blackwood,
an all-new sport utility truck will debut in November.
Jaguar's October sales soared 31.3 percent compared with a year ago and set a
new sales record for the month (4,126). The all-new Jaguar X-TYPE achieved its
best sales month so far as October sales rose 51.0 percent from September.
Volvo's October U.S. sales (10,455) were the second highest in history led by
strong sales of the V70 XC sport wagon and the S60 mid-size sedan (which now
offers an all-wheel drive model). Land Rover October sales (2,264) also were the
second highest in history.
{/TEXT}
{/DOCUMENT}
240276
|
Ford Motor
As referenced in this Ford Motor Company Breaks 24-Year- Old Record as U.S. Sales Soar 34.4%:
FORD MOTOR CO – Go to http://media.ford.com
for news releases and
high-resolution photographs
IMMEDIATE RELEASE
FORD MOTOR CO MPANY BREAKS 24-YEAR- OLD RECORD AS U.S. SALES SOAR 34.4%
AMERICA'S
dt 66383
| |
| Full Doc
| 2001 |
Ford Motor Company's September U.S. Sales Declined 9.7%
Ford Motor Company's September U.S. Sales Declined 9.7% (1K)
Doc #240296: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}EX-20
{SEQUENCE}3
{FILENAME}e100201ex20.txt
{TEXT}
Exhibit 20
NEWS
Contact:
George Pipas
1.313.323.9216
gpipas@ford.com
Media Information Center
1.800.665.1515 or
1.313.621.0504
media@ford.com
Go to http://media.ford.com
for news releases and
high-resolution photographs
IMMEDIATE RELEASE
FORD MOTOR COMPANY'S SEPTEMBER U.S. SALES DECLINED 9.7%
AMERICA'S BEST-SELLING TRUCK SETS NEW SEPTEMBER SALES RECORD
DEARBORN, MI, October 2, 2001 - U.S. customers purchased or leased 295,215 cars
and trucks from Ford, Mercury, Lincoln, Jaguar, Volvo, and Land Rover dealers in
September. This represents a decline of 9.7 percent from a year ago.
Year-to-date, the company's U.S. sales totaled 2.96 million cars and trucks,
down 10.7 percent from last year's record sales.
Ford, America's best-selling brand of cars and trucks, achieved September sales
of 248,331, down 8 percent from a year ago. Ford dealers reported record
September sales (74,787) for Ford F-Series, America's best-selling truck since
1977. The previous record (73,052) was set in 1986. Ford Mustang posted
September sales of 13,919, up 18.1 percent from a year ago. Year-to-date sales
for the Ford Escape reached 115,565 as September sales totaled 12,961.
Jaguar posted record September sales of 3,020, up 4.6 percent from a year ago,
led by the all-new Jaguar X-TYPE. Volvo posted September sales of 7,714, up 1.3
percent from a year ago, on the strength of the S60, Volvo's all-new mid-size
sedan, and the V70 XC sport wagon.
Mercury, Lincoln, and Land Rover had lower sales than a year ago.
{/TEXT}
{/DOCUMENT}
240296
|
Ford Motor
As referenced in this Ford Motor Company's September U.S. Sales Declined 9.7%:
FORD MOTOR CO – Go to http://media.ford.com
for news releases and
high-resolution photographs
IMMEDIATE RELEASE
FORD MOTOR CO MPANY'S SEPTEMBER U.S. SALES DECLINED 9.7%
AMERICA'S BEST-SELLING TRUCK SETS
dt 66402
| |
| Full Doc
| 2001 |
Ford North American Production Update
Ford North American Production Update (2K)
Doc #240297: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}EX-20
{SEQUENCE}3
{FILENAME}e091401ex20.txt
{TEXT}
Exhibit 20
NEWS
Contact:
Della DiPietro
1.313.322.1185
ddipietr@ford.com
Media Information Center
1.800.665.1515 or
1.313.621.0504
media@ford.com
Go to http://media.ford.com
for news releases and
high-resolution photographs
IMMEDIATE RELEASE
FORD NORTH AMERICAN PRODUCTION UPDATE
DEARBORN, Mich., Sept.14, 2001 - Following this week's tragic events, Ford Motor
Company announced reductions in its North American production plans. The company
has experienced parts shortages stemming from freight transportation issues,
particularly in air-freight transport and movement of freight through border
crossings. As we work through this situation, we are focused on assisting the
relief efforts, our employees' peace of mind and maintaining high quality on the
vehicles we produce.
Additionally Ford Motor Company suspended U.S. and Canadian manufacturing
operations at 11:30 a.m. local time today to allow employees to attend noon
memorial services as part of the Day of Prayer and Remembrance. Afternoon
shifts at U.S. and Canadian plants will be suspended early so employees can
attend evening vigils.
While it is difficult to predict the full impact on final production, the
company plans to suspend operations at several assembly plants next week. The
company's current production plan for the third quarter calls for
810,000-820,000 vehicles, down 110,000-120,000 vehicles from the prior forecast,
including all units lost this week and expected losses for the rest of the
month. As a result, third quarter results now will fall short of our previous
forecast for earnings of 10 cents per share before one-time items.
{PAGE}
-2-
Employees at St. Thomas, Wayne Assembly, Dearborn Assembly, Atlanta Assembly and
Ohio Assembly have been told to report back to work on Sept. 24. Wixom
employees have been advised that production will be suspended on Monday,
Sept. 17, but may resume as early as Tuesday, Sept. 18.
{/TEXT}
{/DOCUMENT}
240297
|
Ford Motor
As referenced in this Ford North American Production Update:
Ford Motor
Co – NORTH AMERICAN PRODUCTION UPDATE
DEARBORN, Mich., Sept.14, 2001 - Following this week's tragic events, Ford Motor
Co mpany announced reductions in its North American production plans. The company
has experienced parts shortages
Ford Motor Co – our employees' peace of mind and maintaining high quality on the
vehicles we produce.
Additionally Ford Motor Co mpany suspended U.S. and Canadian manufacturing
operations at 11:30 a.m. local time
dt 66403
| |
| Full Doc
| 2001 |
Ford Motor Company's August U.S. Sales Declined 7.5%
Ford Motor Company's August U.S. Sales Declined 7.5% (2K)
Doc #240298: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}EX-20
{SEQUENCE}3
{FILENAME}e090401ex20.txt
{TEXT}
Exhibit 20
NEWS
Contact:
George Pipas
1.313.323.9216
gpipas@ford.com
Media Information Center
1.800.665.1515 or
1.313.621.0504
media@ford.com
Go to http://media.ford.com
for news releases and
high-resolution photographs
IMMEDIATE RELEASE
FORD MOTOR COMPANY'S AUGUST U.S. SALES DECLINED 7.5%
FORD F-SERIES, AMERICA'S BEST-SELLING TRUCK, SETS NEW AUGUST SALES RECORD;
JAGUAR X-TYPE DEBUTS IN U.S.; JAGUAR AND VOLVO REPORT RECORD AUGUST SALES
DEARBORN, MI, September 4, 2001 - U.S. customers purchased or leased 325,943
cars and trucks from Ford, Mercury, Lincoln, Jaguar, Volvo, and Land Rover
dealers in August, down 7.5 percent from last year's record August sales.
Year-to-date, the company's U.S. sales totaled 2.66 million, down 10.8 percent
from last year's record sales.
Ford dealers reported record August sales (75,038) for Ford F-Series, America's
best-selling truck since 1977. The previous record (71,183) was set last year.
Year-to-date, F-Series' sales totaled 576,069.
Ford Explorer, America's best-selling sport utility vehicle, posted sales of
38,270 - the second highest monthly sales in the 2001 calendar year and 4.7
percent lower than last year's record sales (40,157). Year-to-date, Explorer's
sales totaled 271,565.
Ford trucks, America's best-selling brand of pickups, sport utility vehicles and
vans, eclipsed the 1.5 million sales mark in the 2001 calendar year as August
sales were 192,862, down 1.5 percent compared with a year ago.
{PAGE}
-2-
Jaguar dealers celebrated the arrival of the all-wheel drive X-TYPE sedan by
posting record August sales (3,711). The previous record (3,550) was set last
year. In August, X-TYPE sales were 1,026.
Volvo dealers also reported record August sales of 12,131, up 17.9 percent
compared with a year ago. The previous record (10,553) was set in 1989. August
was the fifth month in a row of higher sales. The all-new S60 mid-size sedan and
the all-wheel drive V70 XC sport wagon continue to drive Volvo's strong sales
performance.
Strong sales results for Ford pickups and sport utility vehicles and record
results at Jaguar and Volvo were not sufficient to offset lower sales for
passenger cars (down 16.3 percent compared with a year ago) and minivans (down
30.1 percent).
The company indicated it was maintaining its previously-announced North American
production plans. The company plans to build 930,000 vehicles in the third
quarter and 980,000 vehicles in the fourth quarter.
{/TEXT}
{/DOCUMENT}
240298
|
Ford Motor
As referenced in this Ford Motor Company's August U.S. Sales Declined 7.5%:
FORD MOTOR CO – Go to http://media.ford.com
for news releases and
high-resolution photographs
IMMEDIATE RELEASE
FORD MOTOR CO MPANY'S AUGUST U.S. SALES DECLINED 7.5%
FORD F-SERIES, AMERICA'S BEST-
dt 66404
| |
| Full Doc
| 2001 |
Ford Motor Company's July U.S. Sales Decline 12.8%
Ford Motor Company's July U.S. Sales Decline 12.8% (2K)
Doc #240301: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}EX-20
{SEQUENCE}3
{FILENAME}e080101ex20.txt
{TEXT}
Exhibit 20
NEWS
Contact:
George Pipas
1.313.323.9216
gpipas@ford.com
Media Information Center
1.800.665.1515 or
1.313.621.0504
media@ford.com
Go to http://media.ford.com
for news releases and
high-resolution photographs
IMMEDIATE RELEASE
-----------------
FORD MOTOR COMPANY'S JULY U.S. SALES DECLINE 12.8%
DEARBORN, MI, August 1, 2001 - U.S. customers purchased or leased 303,043 cars
and trucks from Ford, Mercury, Lincoln, Jaguar, Volvo, and Land Rover dealers in
July, down 12.8 percent from a year ago.
Also, the company indicated that it was maintaining its previously-announced
third quarter North American production plan at 930,000 vehicles.
July sales highlights included:
o Ford remained America's top selling brand of cars and trucks with July
sales of 250,822. In the first seven months of 2001, over 1.9 million U.S.
customers have purchased a new car or truck from a Ford dealer.
o Ford F-Series remained America's top selling truck with July sales of
64,240 and year-to-date sales of 501,031.
o Ford Explorer remained America's top selling sport utility vehicle with
July sales of 36,028 and year-to-date sales of 233,295. It was the second
best July sales in Explorer's 11-year history. The July record (39,550) was
set last year.
o Mercury Mountaineer posted July sales of 4,259, up 19 percent from a year
ago. It was the fourth month in a row of higher sales for Mercury's
redesigned mid-size SUV.
o Volvo dealers reported near-record July sales of 11,228, up 31
{PAGE}
-2-
percent from a year ago. Volvo's sales increase, its fourth month in a row
of higher sales, reflected higher sales of the S40 compact sedan, the
all-new S60 mid-size sedan (which replaced the S70), and the V70 XC sport
wagon (which was introduced last fall).
{/TEXT}
{/DOCUMENT}
240301
|
Ford Motor
As referenced in this Ford Motor Company's July U.S. Sales Decline 12.8%:
FORD MOTOR CO – Go to http://media.ford.com
for news releases and
high-resolution photographs
IMMEDIATE RELEASE
-----------------
FORD MOTOR CO MPANY'S JULY U.S. SALES DECLINE 12.8%
DEARBORN, MI, August 1, 2001 - U.
dt 66407
| |
| Full Doc
| 2001 |
Ford Explorer Sets June Sales Record
Ford Explorer Sets June Sales Record (3K)
Doc #240308: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}EX-20
{SEQUENCE}2
{FILENAME}e070301ex20.txt
{TEXT}
Exhibit 20
NEWS
Contact:
George Pipas
1.313.323.9216
gpipas@ford.com
Media Information Center
1.800.665.1515 or
1.313.621.0504
media@ford.com
Go to http://media.ford.com
for news releases and
high-resolution photogrpahs
IMMEDIATE RELEASE
FORD EXPLORER SETS JUNE SALES RECORD
FORD F-SERIES SETS ALL-TIME SALES RECORD; VOLVO POSTS BEST SALES MONTH EVER
DEARBORN, MI, July 3, 2001 - The Ford Explorer set a June sales record as 42,833
customers took delivery of America's top-selling sport utility vehicle. Ford
Explorer's share of the mid-size sport utility segment has increased every month
since the introduction of the all-new 2002 four-door Explorer. The new Explorer
incorporates independent rear suspension, one of many features that set it apart
from traditional SUVs.
"We appreciate the trust that our customers place in our products and our
company," said Jacques Nasser, President and CEO, Ford Motor Company. "Also, we
want to thank our dealers for their unwavering commitment to serving our
customers."
Overall, U.S. customers purchased or leased 392,412 cars and trucks from Ford,
Mercury, Lincoln, Jaguar, Volvo, and Land Rover dealers, down 6.6 percent from a
year ago.
In addition to the Ford Explorer's record-setting performance, the company's
June sales results were highlighted by:
o Ford F-Series, America's best-selling truck, achieved an all-time monthly
sales record of 91,481. The previous F-Series monthly sales record was
90,522 (set March 2000). The
{PAGE}
-2-
previous June sales record (90,370) was set 1978.
o Ford dealers delivered an any-month record 75,973 sport utility vehicles,
up 12 percent from a year ago. The previous monthly sales record (75,216)
was set March 2001. Ford dealers' line of "No Boundaries" SUVs (Ford
Escape, Explorer, Expedition, and Excursion) are the best-selling brand of
sport utility vehicles in the U.S. with year-to-date sales of 390,693, up
six percent from the same period a year ago.
o Mercury dealers reported higher sales for the all-new Mercury Mountaineer.
In June, 4,817 customers took delivery of Mercury's stylish sport utility
vehicle, up six percent from a year ago.
o Lincoln dealers reported June sales of 16,846, down slightly (two percent)
from a year ago. The Lincoln LS mid-size sedan set a new June sales record
(4,921).
o Volvo dealers reported their highest monthly U.S. sales ever (15,104), up
14.3 percent from a year ago (the previous best month). The increase in
sales was centered on the S60 and V70, Volvo's all-new mid-size sedan and
station wagons (including the all-wheel-drive cross-country version, the
V70 XC).
o Jaguar dealers reported June sales of 3,448, down nine percent from last
year's record sales.
o Land Rover dealers reported June sales of 2,427, up two percent from a year
ago, and the highest sales month of 2001.
The company indicated it was maintaining its previously-announced third quarter
North American production plan at 930,000 vehicles.
{/TEXT}
{/DOCUMENT}
240308
|
Ford Motor
As referenced in this Ford Explorer Sets June Sales Record:
Ford Motor Co – our customers place in our products and our
company," said Jacques Nasser, President and CEO, Ford Motor Co mpany. "Also, we
want to thank our dealers for their unwavering commitment to serving our
dt 66414
| |